Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
出版年份 2020 全文链接
标题
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 13, Pages 4579
出版商
MDPI AG
发表日期
2020-06-29
DOI
10.3390/ijms21134579
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Prevalence and mutational determinants of high tumor mutation burden in breast cancer
- (2020) R. Barroso-Sousa et al. ANNALS OF ONCOLOGY
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
- (2020) Adrienne G. Waks et al. ANNALS OF ONCOLOGY
- Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
- (2020) Po‐Han Lin et al. CANCER SCIENCE
- BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer
- (2020) Amal Tazzite et al. CURRENT DRUG TARGETS
- PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
- (2020) Heng Zhu et al. Molecular Cancer
- Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
- (2020) Hisamitsu Takaya et al. Scientific Reports
- Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells
- (2020) Manuel Abreu et al. Journal of Clinical Medicine
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
- (2020) T. Karn et al. ANNALS OF ONCOLOGY
- Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer
- (2020) Aryana M. Razmara et al. CLINICAL & EXPERIMENTAL METASTASIS
- Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
- (2020) Álvaro Lahiguera et al. EMBO Molecular Medicine
- Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
- (2020) Priyanka Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
- (2020) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
- (2020) Man Yee Keung et al. Journal of Clinical Medicine
- Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters (CTC-clusters) as Predictors of Patient Outcomes
- (2020) Clotilde Costa et al. Cancers
- Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
- (2020) Ghulam Rehman Mohyuddin et al. BMC CANCER
- Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy
- (2020) Parham Jabbarzadeh Kaboli et al. PHARMACOLOGICAL RESEARCH
- Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding
- (2019) Sofia Gkountela et al. CELL
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
- (2019) Shahrzad Jalali et al. Blood Cancer Journal
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
- (2019) Lorenzo Castagnoli et al. ONCOGENE
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liquid biopsy in breast cancer: A comprehensive review
- (2019) Sahar Alimirzaie et al. CLINICAL GENETICS
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- 4ORelationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
- (2019) S Loi et al. ANNALS OF ONCOLOGY
- Targeting the PI3-kinase pathway in triple-negative breast cancer
- (2019) J Pascual et al. ANNALS OF ONCOLOGY
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- Dissecting PARP inhibitor resistance with functional genomics
- (2019) Stephen J Pettitt et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
- (2019) Javier Cortés et al. Future Oncology
- Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.
- (2019) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC).
- (2019) Luca Cavallone et al. JOURNAL OF CLINICAL ONCOLOGY
- RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).
- (2019) Anne Patsouris et al. JOURNAL OF CLINICAL ONCOLOGY
- FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
- (2019) Piao Li et al. JOURNAL OF IMMUNOLOGY
- MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
- (2019) Thijs S Stutvoet et al. JOURNAL OF PATHOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastasis Stemming from Circulating Tumor Cell Clusters
- (2019) Min Yu TRENDS IN CELL BIOLOGY
- Contribution of Epithelial Plasticity to Therapy Resistance
- (2019) Patricia G. Santamaría et al. Journal of Clinical Medicine
- FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
- (2019) M Oliveira et al. ANNALS OF ONCOLOGY
- Circulating Tumor Cell Clusters in Metastatic Breast Cancer Patients: a SWOG S0500 Translational Medicine Study.
- (2019) Costanza Paoletti et al. CLINICAL CANCER RESEARCH
- Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
- (2019) David M. Goldenberg et al. mAbs
- Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
- (2019) Yuan Yuan et al. Scientific Reports
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
- (2019) Isaac Garcia-Murillas et al. JAMA Oncology
- Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
- (2019) Park et al. Cancers
- Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients
- (2019) Silpa Nuthalapati et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
- (2019) Jacob J. Adashek et al. Cells
- CD133 in Breast Cancer Cells: More than a Stem Cell Marker
- (2019) Federica Brugnoli et al. Journal of Oncology
- 1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
- (2019) A Marabelle et al. ANNALS OF ONCOLOGY
- LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- (2019) P Schmid et al. ANNALS OF ONCOLOGY
- LBA9Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
- (2019) V C Diéras et al. ANNALS OF ONCOLOGY
- Depletion of DNA damage binding protein 2 sensitizes triple‐negative breast cancer cells to poly ADP‐ribose polymerase inhibition by destabilizing Rad51
- (2019) Lin Zhao et al. CANCER SCIENCE
- Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
- (2019) Mark Robson et al. EUROPEAN JOURNAL OF CANCER
- Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
- (2019) Rebecca S Kristeleit et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer
- (2019) Hariprasad Thangavel et al. Journal of Clinical Medicine
- Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
- (2019) Ramy R. Saleh et al. Frontiers in Oncology
- TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer
- (2019) Brian D. Lehmann et al. CLINICAL CANCER RESEARCH
- Triple negative breast cancer: A thorough review of biomarkers
- (2019) Jesse Lopes da Silva et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer
- (2019) Maria Rusan et al. EUROPEAN JOURNAL OF CANCER
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- Molecular stratification within triple-negative breast cancer subtypes
- (2019) Dong-Yu Wang et al. Scientific Reports
- First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
- (2019) Minetta C Liu et al. Cancer Management and Research
- CTC clusters induced by heparanase enhance breast cancer metastasis
- (2018) Rong-rui Wei et al. ACTA PHARMACOLOGICA SINICA
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
- (2018) Joyce O’Shaughnessy et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
- (2018) Eileen M. O'Reilly et al. CANCER
- Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
- (2018) L. Gerratana et al. CANCER TREATMENT REVIEWS
- Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer
- (2018) Xiaoran Liu et al. Chinese Journal of Cancer Research
- The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer
- (2018) Alice Lallo et al. CLINICAL CANCER RESEARCH
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
- (2018) Daniel G. Stover et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- (2018) Jose Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
- (2018) Nicholas Borcherding et al. JOURNAL OF MOLECULAR BIOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
- (2018) George E. Ronson et al. Nature Communications
- AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
- (2018) Xiangbing Meng et al. Cancers
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
- (2018) Brittany Haynes et al. CANCER TREATMENT REVIEWS
- Antibody–drug conjugates in triple negative breast cancer
- (2018) Nancy Tray et al. Future Oncology
- Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.
- (2018) Romualdo Barroso-Sousa et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
- (2018) Sònia Palomeras et al. MOLECULES
- WNT Signaling in Cancer Immunosurveillance
- (2018) Lorenzo Galluzzi et al. TRENDS IN CELL BIOLOGY
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
- (2018) Alexandra Thomas et al. OncoImmunology
- Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer
- (2018) Joseph Sparano et al. JAMA Oncology
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
- (2018) Jun Tian et al. BRITISH JOURNAL OF CANCER
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers
- (2018) Antonio Marzio et al. MOLECULAR CELL
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA2 controls DNA:RNA hybrid level at DSBs by mediating RNase H2 recruitment
- (2018) Giuseppina D’Alessandro et al. Nature Communications
- Capivasertib Active against AKT1-Mutated Cancers
- (2018) Cancer Discovery
- A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
- (2018) Kaiming Sun et al. Oncotarget
- The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
- (2018) Massimo Cristofanilli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-1 and cancer: molecular mechanisms and polymorphisms
- (2017) Arash Salmaninejad et al. IMMUNOGENETICS
- BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness
- (2017) Pawel Domagala et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities
- (2017) Jyotika Rajawat et al. MEDICINAL RESEARCH REVIEWS
- Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)
- (2017) Fei Ma et al. MEDICINE
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Interferon-beta represses cancer stem cell properties in triple-negative breast cancer
- (2017) Mary R. Doherty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
- (2017) François Bertucci et al. Current Oncology Reports
- BETting on combination to overcome PARPi resistance
- (2017) Youyou Zhang et al. Oncotarget
- Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
- (2017) Floriana Morgillo et al. Oncotarget
- AR Signaling in Breast Cancer
- (2017) Bilal Rahim et al. Cancers
- Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis
- (2017) Wenzhe Li et al. Scientific Reports
- Curcumin Suppresses Proliferation and Migration and Induces Apoptosis on Human Placental Choriocarcinoma Cells via ERK1/2 and SAPK/JNK MAPK Signaling Pathways
- (2016) W. Lim et al. BIOLOGY OF REPRODUCTION
- CTCs in early breast cancer: A path worth taking
- (2016) Roberta Maltoni et al. CANCER LETTERS
- Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
- (2016) Heather A. Parsons et al. CLINICAL CANCER RESEARCH
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
- (2016) W. J. Janni et al. CLINICAL CANCER RESEARCH
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
- (2016) Xi-wen Bi et al. Journal of Hematology & Oncology
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
- (2016) Bernard Pereira et al. Nature Communications
- The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
- (2016) Yan Mao et al. PLoS One
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
- (2015) Christopher J. Lord et al. Annual Review of Medicine
- Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
- (2015) C. Paoletti et al. CLINICAL CANCER RESEARCH
- Taselisib (GDC-0032), a Potent -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
- (2015) Z. S. Zumsteg et al. CLINICAL CANCER RESEARCH
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
- (2015) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis
- (2015) G Maric et al. ONCOGENE
- The biology of circulating tumor cells
- (2015) K Pantel et al. ONCOGENE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
- (2015) Rohit Prakash et al. Cold Spring Harbor Perspectives in Biology
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer
- (2015) Francesca Collina et al. Biomed Research International
- Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers
- (2015) Pawel Domagala et al. PLoS One
- Wip1 and ATM in tumor evolution: role for BRCA1.
- (2015) Doria Filipponi et al. Oncotarget
- Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
- (2014) Priyanka Sharma et al. BREAST CANCER RESEARCH AND TREATMENT
- Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
- (2014) Nicola Aceto et al. CELL
- Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
- (2014) M. J. M. Magbanua et al. CLINICAL CANCER RESEARCH
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- BRCA1, a ‘complex’ protein involved in the maintenance of genomic stability
- (2014) Kienan I. Savage et al. FEBS Journal
- Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients
- (2014) Jordan Madic et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24−/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells
- (2014) MATEUSZ OPYRCHAL et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
- (2014) Jeffrey B. Smerage et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
- (2014) Brigitte Rack et al. JNCI-Journal of the National Cancer Institute
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
- (2014) François-Clément Bidard et al. LANCET ONCOLOGY
- SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
- (2014) D. Sussman et al. MOLECULAR CANCER THERAPEUTICS
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells
- (2014) M Bartucci et al. ONCOGENE
- VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
- (2014) D Zhao et al. ONCOGENE
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
- (2014) P. Muller et al. Cancer Immunology Research
- Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts
- (2014) Suling Liu et al. Stem Cell Reports
- Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial†
- (2013) Z. F. Jiang et al. ANNALS OF ONCOLOGY
- Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity
- (2013) Christine L. Chaffer et al. CELL
- Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells
- (2013) Seog-Young Kim et al. CELLULAR SIGNALLING
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
- (2013) Y. Yan et al. CLINICAL CANCER RESEARCH
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy
- (2013) Veronika Mikulová et al. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
- (2013) M. Yu et al. SCIENCE
- PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
- (2012) Roy RL Bastien et al. BMC Medical Genomics
- Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast Cancer
- (2012) Elisabetta Munzone et al. Clinical Breast Cancer
- Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer
- (2012) Hong Lin et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma
- (2012) Yan Lin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Circulating tumour cells in non-metastatic breast cancer: a prospective study
- (2012) Anthony Lucci et al. LANCET ONCOLOGY
- RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
- (2012) Min Yu et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors
- (2012) Edward H Cho et al. PHYSICAL BIOLOGY
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy
- (2011) A. Giordano et al. ANNALS OF ONCOLOGY
- Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer
- (2011) Yasuyo Ohi et al. HISTOPATHOLOGY
- Circulating tumor cells: approaches to isolation and characterization
- (2011) Min Yu et al. JOURNAL OF CELL BIOLOGY
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype
- (2011) S. Ricardo et al. JOURNAL OF CLINICAL PATHOLOGY
- LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling
- (2011) Hui-Wen Lue et al. PLoS One
- Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells
- (2011) Pham Van Phuc et al. OncoTargets and Therapy
- Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
- (2010) F.- C. Bidard et al. ANNALS OF ONCOLOGY
- Secondary mutations of BRCA1/2 and drug resistance
- (2010) Kiranjit K. Dhillon et al. CANCER SCIENCE
- Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
- (2010) A. A. N. Rose et al. CLINICAL CANCER RESEARCH
- Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
- (2010) S. Riethdorf et al. CLINICAL CANCER RESEARCH
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
- (2010) Rafael Cubas et al. Molecular Cancer
- Malignant cells facilitate lung metastasis by bringing their own soil
- (2010) D. G. Duda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models
- (2010) H. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circulating tumour cells: their utility in cancer management and predicting outcomes
- (2010) Matthew G. Krebs et al. Therapeutic Advances in Medical Oncology
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Differential Expression of PTEN-Targeting MicroRNAs miR-19a and miR-21 in Cowden Syndrome
- (2008) Marcus G. Pezzolesi et al. AMERICAN JOURNAL OF HUMAN GENETICS
- The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
- (2008) M. Schmidt et al. CANCER RESEARCH
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
- (2008) J. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
- (2008) Shidong Jia et al. NATURE
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications
- (2007) F. Nole et al. ANNALS OF ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started